Cancer biomarkers : section A of Disease markers最新文献

{"title":"Erratum.","authors":"","doi":"10.3233/CBM-179556","DOIUrl":"https://doi.org/10.3233/CBM-179556","url":null,"abstract":"Levav, I., Gilboa, S. & Ruiz, F. ‘Demoralization and gender differences in a kibbutz’ (Vol. 21, pp. 1019–1028). On page 1022, the first sentence of the Results section should read ‘The findings refer to (1) the extent to which the kibbutz succeeded in achieving gender equality; and (2) the test of the psychosocial hypotheses’. On page 1023 under the heading Marital status the second sentence should read ‘Additionally, married men (TV = 136) had the second lowest mean scores, 0–90’.","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"521"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-179556","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37066407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer.","authors":"Dimitra-Ioanna Lampropoulou,&nbsp;Gerasimos Aravantinos,&nbsp;Hector Katifelis,&nbsp;Foivos Lazaris,&nbsp;Konstantinos Laschos,&nbsp;Theodosios Theodosopoulos,&nbsp;Christos Papadimitriou,&nbsp;Maria Gazouli","doi":"10.3233/CBM-182383","DOIUrl":"https://doi.org/10.3233/CBM-182383","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer is the fourth cause of cancer related death. Drug resistance and toxicity remain major clinical issues. HOTAIR and MALAT1 are long non-coding RNAS that affect cellular proliferation, apoptosis and drug resistance; their up-regulation has been linked with a poor prognosis.</p><p><strong>Objective: </strong>Investigation of the association between rs4759314 HOTAIR and rs3200401 MALAT1 polymorphisms and irinotecan-based chemotherapy in terms of drug efficacy and toxicity.</p><p><strong>Methods: </strong>Samples from 98 patients receiving different regimens of irinotecan-based therapy were included. Efficacy and toxicity were evaluated. KRAS mutation, rs3200401 HOTAIR and rs4759314 MALAT1 polymorphisms genotyping in the tumors and peripheral blood respectively were performed with PCR.</p><p><strong>Results: </strong>Neither rs3200401 MALAT1 nor rs4759314 HOTAIR polymorphism are associated with response to treatment regimens. Rs4759314 was also not associated with increased toxicity in patients receiving irinotecan-based regimens. CT genotype of rs3200401 was associated with significantly reduced overall survival. An association between KRAS mutation and AG/GG genotypes in the rs4759314 was detected.</p><p><strong>Conclusions: </strong>CT genotype of rs3200401 MALAT1 polymorphism could serve as a toxicity biomarker. Carriers of the G allele of the rs4759314 HOTAIR are more likely to be carriers of KRAS mutations too. However, further studies in larger patient populations are required.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"213-221"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182383","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ginsenoside impedes proliferation and induces apoptosis of human osteosarcoma cells by down-regulating β-catenin.","authors":"Xue-Feng Li,&nbsp;Guo-Qing Zhao,&nbsp;Long-Yun Li","doi":"10.3233/CBM-182046","DOIUrl":"https://doi.org/10.3233/CBM-182046","url":null,"abstract":"<p><strong>Background: </strong>Osteosarcoma (OS) is the most commonly occurred primary bone malignancy with high incident rates among children and adolescents. In pharmacologic treatment, the drug ginsenoside has been shown to exert anticancer effects on several malignant diseases. The purpose of this research was to investigate the effect of ginsenoside on the apoptosis and proliferation of human OS MG-63 and Saos-2 cells by regulating the expression of β-catenin.</p><p><strong>Methods: </strong>Human OS MG-63 and Saos-2 cells were assigned into control group, and four groups with treatment by varying concentrations (12.5 μg/mL, 25 μg/mL, 50 μg/mL and 100 μg/mL) of ginsenoside, respectively. Cell growth after treatment was observed through cell slides. The proliferation rate of MG-63 and Saos-2 cells in each group was detected by CCK-8. After cell transfection at 48 h, cell cycle and cell apoptosis were detected by FITC-Annexin V staining and flow cytometry. The protein and mRNA expressions of β-catenin, Cyclin D1, Bcl-2, Bax and cleaved caspase-3 were detected by RT-qPCR and western blot analysis.</p><p><strong>Results: </strong>With increased exposure and concentration of ginsenoside, the cell density, total cell numbers and the absorbance of MG-63 and Saos-2 cells gradually decreased. FITC-Annexin V and FITC-Annexin V/PI staining demonstrated that the cell proportion at S phase decreased, whereas the total apoptotic rate of MG-63 and Saos-2 cells was increased. Furthermore, RT-qPCR and western blot analysis highlighted a gradual decrease in protein and mRNA expressions of β-catenin, Bcl-2 and Cyclin D1, while an elevation in those of Bax and cleaved caspase-3.</p><p><strong>Conclusion: </strong>The results of this study demonstrate that ginsenoside inhibits proliferation and promotes apoptosis of human OS MG-63 and Saos-2 cells by reducing the expressions of β-catenin, Bcl-2 and Cyclin D1 and increasing the expression of Bax and cleaved caspase-3.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"395-404"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37088542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defensin alpha 6 (DEFA6) is a prognostic marker in colorectal cancer.","authors":"Dongjun Jeong,&nbsp;Hyeongjoo Kim,&nbsp;Doyeon Kim,&nbsp;Seona Ban,&nbsp;Seunghyun Oh,&nbsp;Sanghee Ji,&nbsp;DongHyun Kang,&nbsp;Hyunyong Lee,&nbsp;Tae Sung Ahn,&nbsp;Han Jo Kim,&nbsp;Sang Byung Bae,&nbsp;Moon Soo Lee,&nbsp;Chang-Jin Kim,&nbsp;Hyog Young Kwon,&nbsp;Moo-Jun Baek","doi":"10.3233/CBM-182221","DOIUrl":"https://doi.org/10.3233/CBM-182221","url":null,"abstract":"<p><p>Defensin alpha 6 (DEFA6) is a member of the alpha defensin family of microbicidal and cytotoxic peptides that defend against bacteria and viruses. Here, we provide a novel function of DEFA6 in tumorigenesis of colorectal cancer (CRC) in vitro and in vivo. Specifically, DEFA6 is highly expressed in both CRC cancer cell lines as well as patient-derived samples at the level of RNA and protein. By shRNA-mediated loss of function of DEFA6, we found that proliferation, migration, invasion, colony forming ability of CRC cell lines were impaired in the absence of DEFA6 in vitro. Furthermore, DEFA6-deficient cancer cells exhibited significantly reduced growth rates compared to control cells in vivo. More importantly, by analyzing 352 patient-derived samples, we revealed that DEFA6 is associated with overall survival rate of CRC patients and thus an independent prognostic marker for CRC. These results suggest that DEFA6 plays an essential oncogenic role in CRC and serves a good therapeutic target for the disease.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"485-495"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-182221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37108497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet indices in non-small cell lung cancer patients with brain metastases.","authors":"Ming-Ming Li,&nbsp;Xin Wang,&nbsp;Zhi-Yuan Yun,&nbsp;Rui-Tao Wang,&nbsp;Kai-Jiang Yu","doi":"10.3233/CBM-192393","DOIUrl":"https://doi.org/10.3233/CBM-192393","url":null,"abstract":"<p><strong>Background: </strong>Platelets play a crucial role in cancer progression and metastasis. The aim of the present study was to assess the relationship between platelet indices and non-small cell lung cancer (NSCLC) with brain metastases.</p><p><strong>Methods: </strong>Between January 2015 and December 2017, 232 NSCLC patients with brain metastases and 244 NSCLC patients without metastases were retrospectively analyzed. Patients' clinicopathological characteristics data were collected.</p><p><strong>Results: </strong>Platelet count was increased and mean platelet volume (MPV) was reduced in NSCLC patients with brain metastases compared with NSCLC patients without metastases. In addition, the prevalence of NSCLC decreased as MPV quartiles increased. After adjusting for other risk factors, the ORs (95% CIs) for NSCLC brain metastases according to MPV quartiles were 1.757 (1.024-3.015), 2.097 (1.209-3.635), 1.517 (0.874-2.635), and 1.000, respectively.</p><p><strong>Conclusions: </strong>MPV is reduced in NSCLC patients with brain metastases compared with NSCLC patients without metastases. Moreover, MPV is found to be independently associated with the presence of NSCLC brain metastases.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"515-519"},"PeriodicalIF":3.1,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-192393","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37108498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deregulation of sialidases in human normal and tumor tissues.","authors":"Matilde Forcella,&nbsp;Alessandra Mozzi,&nbsp;Federico M Stefanini,&nbsp;Alice Riva,&nbsp;Samantha Epistolio,&nbsp;Francesca Molinari,&nbsp;Elisabetta Merlo,&nbsp;Eugenio Monti,&nbsp;Paola Fusi,&nbsp;Milo Frattini","doi":"10.3233/CBM-170548","DOIUrl":"https://doi.org/10.3233/CBM-170548","url":null,"abstract":"<p><strong>Background: </strong>Aberrant sialylation is a characteristic feature associated with cancer. The four types of mammalian sialidases identified to date have been shown to behave in different manners during carcinogenesis. While NEU1, NEU2 and NEU4 have been observed to oppose malignant phenotypes, the membrane-bound sialidase NEU3 was revealed to promote cancer progression.</p><p><strong>Objectives: </strong>With the aim of improving the knowledge about sialidases deregulation in various cancer types, we investigated the amount of NEU1, NEU3 and NEU4 transcripts in paired normal and tumor tissues from 170 patients with 11 cancer types.</p><p><strong>Methods: </strong>mRNA was extracted from patients' tissue specimens and retrotranscribed into cDNA, which was quantified by Real-Time PCR.</p><p><strong>Results: </strong>We found NEU1 and NEU3 to be up regulated, while NEU4 was down regulated in most cancer types. In particular, colorectal cancer tissues showed the highest increase in NEU3 expression. Both NEU1 and NEU3 showed a strong up-regulation in ovarian cancer.</p><p><strong>Conclusions: </strong>Our data show that human sialidases are expressed at different levels in healthy tissues and are strongly deregulated in tumors. Moreover, sialidases expression in our European cohort showed significant differences from Asian populations. Some of these peculiar features open potential applications of sialidases in cancer diagnosis and therapy.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"591-601"},"PeriodicalIF":3.1,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-170548","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35689083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upregulation of the long noncoding RNA FOXD2-AS1 predicts poor prognosis in esophageal squamous cell carcinoma.","authors":"Jie Bao,&nbsp;Chenjie Zhou,&nbsp;Jiaqing Zhang,&nbsp;Jiaqiang Mo,&nbsp;Qing Ye,&nbsp;Junming He,&nbsp;Jingfang Diao","doi":"10.3233/CBM-170260","DOIUrl":"https://doi.org/10.3233/CBM-170260","url":null,"abstract":"<p><strong>Background: </strong>The long non-coding RNA FOXD2-AS1 is highly expressed in non-small cell lung cancer and promotes malignant progression. However, the role of FOXD2-AS1 in esophageal squamous cell carcinoma (ESCC) is still unclear.</p><p><strong>Objective: </strong>In this study, we examined the relationships between the expression level of FOXD2-AS1 and the outcome of ESCC patients.</p><p><strong>Methods: </strong>Expression of FOXD2-AS1 was evaluated in cancer tissue and adjacent non-tumor tissue samples from 147 ESCC patients who received radical surgical resection using qRT-PCR. The correlations between the expression level of FOXD2-AS1 and patients' overall (OS) and disease free survival (DFS) were analyzed.</p><p><strong>Results: </strong>FOXD2-AS1 expression was upregulated in ESCC tissue than that in adjacent non-tumor tissue samples (P< 0.001). Kaplan-Meier analysis showed that high FOXD2-AS1 expression was correlated with poor prognosis in ESCC patients. Patients with a high level of FOXD2-AS1 had a shorter OS and DFS than those with a low level of FOXD2-AS1 (P= 0.005 and 0.0001, respectively). On multivariate analysis, the hazard ratio of FOXD2-AS1 expression was 1.66 (95% CI = 1.04-2.64, P= 0.033) for OS and 2.68 (95% CI = 1.49-4.82, P= 0.001) for DFS.</p><p><strong>Conclusions: </strong>Overall, our results provided convinced evidence that FOXD2-AS1 may serve as a predictive marker for ESCC patients' survival.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"527-533"},"PeriodicalIF":3.1,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-170260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35696286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of immune function, hemorheological alterations and prognosis in colorectal cancer patients with different traditional Chinese medicine syndromes.","authors":"Cheng-Yang Wang,&nbsp;Huan-Zhang Ding,&nbsp;Xiao Tang,&nbsp;Ze-Geng Li","doi":"10.3233/CBM-170805","DOIUrl":"https://doi.org/10.3233/CBM-170805","url":null,"abstract":"<p><strong>Objective: </strong>The present study investigates the differences in immune function, hemorheological alterations and prognostic evaluation in colorectal cancer (CRC) patients with different traditional Chinese medicine (TCM) syndromes.</p><p><strong>Methods: </strong>A total of 128 patients, diagnosed as stage II and III of CRC, were recruited. They were assigned into three TCM syndromes: deficiency syndrome, excess syndrome, and syndrome of intermingled deficiency and excess, and another 53 healthy individuals were selected as the control. Flow cytometry was used to determine the peripheral blood lymphocyte subsets (the levels of CD+3, CD+4, CD+8, NK cells, and the ratios of CD+4/CD+8, Th1/Th2 and Tc1/Tc2). Whole blood viscosity (WBV), plasma viscosity (PV), hematocrit (Hct), erythrocyte sedimentation rate (ESR), plasma fibrinogen concentration (PFC) were measured using a fully-automatic blood rheological instrument. The univariate analysis and Cox regression analysis were conducted to evaluate the prognosis of CRC patients with different TCM syndromes.</p><p><strong>Results: </strong>Compared with healthy individuals, CRC patients with three different syndromes had lower levels of CD+3, CD+4, NK cells, and ratios of CD+4/CD+8, Th1/Th2 and Tc1/Tc2, but higher level of CD+8, WBV, PV, Hct, ESR and PFC. Besides, patients with excess syndrome showed the highest levels of CD3+, CD4+ and NK cells, and ratios of CD+4/CD+8, Th1/Th2 and Tc1/Tc2, but the lowest level of CD+8 among three syndromes, and those with deficiency syndrome showed an opposite trend. Compared with patients with excess syndrome, those with deficiency syndrome showed decreased WBV, PV, Hct, ESR and PFC. The pathological type, surgical approach, tumor node metastasis (TNM) stage, liver metastasis, TCM treatment time and different TCM syndromes were independent factors of prognostic survival in CRC patients except perioperative blood transfusion volume.</p><p><strong>Conclusions: </strong>Taken together, we conclude that patients with TCM deficiency syndrome has lower immune function and poorer prognosis while patients with TCM excess syndrome has higher immune function and better prognosis of CRC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"701-710"},"PeriodicalIF":3.1,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-170805","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35281175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.","authors":"Xiangjun Guo,&nbsp;Jiaxin Shi,&nbsp;Yan Wen,&nbsp;Mengmeng Li,&nbsp;Qin Li,&nbsp;Xiaomei Li,&nbsp;Jiashu Li","doi":"10.3233/CBM-170401","DOIUrl":"https://doi.org/10.3233/CBM-170401","url":null,"abstract":"<p><strong>Background: </strong>High-mobility group A2 (HMGA2) has been investigated to be associated with tumorigenesis; however, the expression pattern and clinical significance of HMGA2 in non-small cell lung cancer (NSCLC) remains poorly understood. The purpose of this study is to examine the expression of HMGA2 and to analyze its relationships with respect to clinico-pathological features and patient survival in NSCLC.</p><p><strong>Methods: </strong>The expression level of HMGA2 was examined by Western blot and immunohistochemistry in NSCLC cells and tissues. The relationship between HMGA2 expression and survival of NSCLC patients was calculated by a Kaplan-Meier method and the evaluation of risk factor was determined by the multiple regression analysis.</p><p><strong>Results: </strong>NSCLC tissues exhibited a higher expression level of HMGA2 compared to normal tissues (p< 0.05) and the expression level of HMGA2 was significantly associated with poor differentiation of NSCLC (p< 0.05), lymph node metastasis (p< 0.05) and advanced clinical stage (p< 0.05). Besides, HMGA2 was also confirmed to be elevated in NSCLC cells by Western blot. Moreover, increased expression of HMGA2 correlated with decreased survival of NSCLC patients (p< 0.05).</p><p><strong>Conclusions: </strong>HMGA2 was highly expressed in NSCLC tissues and cells and its overexpression was correlated with low-grade differentiation, lymph node metastasis, advanced clinical stage and poor survival time of NSCLC, which suggested that it could serve as a potential molecular marker and prognostic index for NSCLC.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"547-555"},"PeriodicalIF":3.1,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-170401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35689116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.","authors":"Gabriele Ricco,&nbsp;Daniela Cavallone,&nbsp;Chiara Cosma,&nbsp;Gian Paolo Caviglia,&nbsp;Filippo Oliveri,&nbsp;Alessandra Biasiolo,&nbsp;Maria Lorena Abate,&nbsp;Mario Plebani,&nbsp;Antonina Smedile,&nbsp;Ferruccio Bonino,&nbsp;Patrizia Pontisso,&nbsp;Maurizia Rossana Brunetto","doi":"10.3233/CBM-170551","DOIUrl":"https://doi.org/10.3233/CBM-170551","url":null,"abstract":"<p><strong>Background: </strong>The role of serum biomarkers in the surveillance of hepatocellular carcinoma (HCC) is controversial.</p><p><strong>Objective: </strong>We assessed the diagnostic performances of alpha-fetoprotein (AFP) and protein-induced by vitamin-K-absence/antagonist-II (PIVKA-II) in 388 cirrhotic patients with chronic liver disease (CLD).</p><p><strong>Methods: </strong>Biomarkers were quantified by automated chemiluminescent-enzyme-immunoassays (Fujirebio, Tokyo, Japan) at HCC diagnosis in 258 patients (204 males; median age 66.9 years) and in 130 cirrhotics without HCC (104 males; median-age 60.6 years). CLD etiology in HCC/non-HCC was CHB in 48/35, CHC in 126/56 and Non-Viral in 84/39.</p><p><strong>Results: </strong>Overall AUROC values for AFP and PIVKA-II were 0.698 (95%CI = 0.642-0.753, P< 0.001) and 0.780 (95%CI = 0.730-0.831, P< 0.001). AFP/PIVKA-II AUROC (95%CI) were: 0.822 (0.728-0.915)/0.833 (0.739-0.926) in CHB, 0.648 (0.560-0.736)/0.732 (0.650-0.814) in CHC; 0.640 (0.540-0.740)/0.806 (0.722-0.889) in Non-Viral-CLD. AFP/PIVKA-II diagnostic accuracy was 40.5-59.8%/62.7-73.5% and combining both markers 78.2% for CHB, 77% for Non-Viral-CLD and 75% for CHC. AFP correlated with ALT in HCC patients with CHC (ρ= 0.463/P< 0.001) and Non-Viral CLD (ρ= 0.359/P= 0.047), but not in CHB (treated with antivirals). PIVKA-II correlated with tumour size independently of CLD-etiology (P< 0.001) and AFP in CHB patients only (P= 0.007).</p><p><strong>Conclusion: </strong>The diagnostic performance of AFP and PIVKA-II is significantly influenced by the etiology and activity of CLD; their combination provides a better diagnostic accuracy.</p>","PeriodicalId":520578,"journal":{"name":"Cancer biomarkers : section A of Disease markers","volume":" ","pages":"603-612"},"PeriodicalIF":3.1,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/CBM-170551","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35689084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}